The UC San Diego (UCSD) Moores Cancer Center (MCC) has a rich history as a matrix, NCI-designated comprehensive cancer center, now with 239 members from 28 UCSD departments. Peer-reviewed MCC funding is $118.3 million (direct costs), of which $33.2 million is from the NCI. An additional $15.6 million from non-peer-reviewed sources results in total direct-cost funding of $133.9 million. We have published over 4000 cancer-focused papers in the funding period (20% inter- or intra-programmatic;10% in journals with an impact factor >15). MCC is surrounded by several other major life-science research institutes and 489 biotechnology companies in San Diego/La Jolla, the 2""""""""''largest life-sciences cluster in the US. MCC is the only NCI-designated comprehensive cancer center in this region. MCC leverages this advantage to save lives by transforming cancer prevention, detection, and care (mission) and to make personalized cancer medicine a reality (vision). This is our first renewal application as a consortium center with partner San Diego State University (SDSU), thus formalizing long-standing, productive collaborations between MCC and SDSU. As designed, the MCC building 1) stimulates interdisciplinary collaboration between physicians and scientists in the Center's Divisions of Basic Science, Clinical Science, and Population Science, 2) assembles the extensive NCI-supported Shared Resources in a common, accessible site, and 3) acts as an academia-industry hub for translational cancer researchers within the public and private sectors of San Diego. The vast majority of members are in the MCC building or on the UCSD campus;others are in nearby La Jolla institutes. This application reports on six Research Programs: Cancer Biology and Signaling, Cancer Genomes and Networks, Hematologic Malignancies, Solid Tumor Therapeutics, Cancer Prevention, and Reducing Cancer Disparities. We also propose seven Shared Resources: Biorepository and Tissue Technology, Biostatistics, Genomics and Bioinformatics, Microscopy, Flow Cytometry, Transgenic Mouse, Diet and Physical Activity. All Programs and Resources reflect the scientific strengths and goals of the MCC. MCC is poised to leverage its exceptional basic and population sciences and San Diego-wide collaborations (academic and private-sector) in developing innovative science-based cancer prevention and treatment. This application summarizes our investments, recruitments, collaborations, organizational changes, plans, and progress toward this goal. CCSG funding advances the UCSD Moores Cancer Center mission to save lives by transforming cancer prevention, detection, and care, and vision to make personalized cancer medicine a reality. The Cancer Center places the highest priority on basic discovery and its translation (via leveraging San Diego's unique academia-industry environment) into major clinical advances that reduce the burden of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA023100-28S3
Application #
8920334
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1996-07-01
Project End
2019-04-30
Budget Start
2014-09-01
Budget End
2015-04-30
Support Year
28
Fiscal Year
2014
Total Cost
$33,334
Indirect Cost
$11,828
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Akers, Johnny C; Ramakrishnan, Valya; Yang, Isaac et al. (2016) Optimizing preservation of extracellular vesicular miRNAs derived from clinical cerebrospinal fluid. Cancer Biomark 17:125-32
Hoffmann, Hanne M; Trang, Crystal; Gong, Ping et al. (2016) Deletion of Vax1 from Gonadotropin-Releasing Hormone (GnRH) Neurons Abolishes GnRH Expression and Leads to Hypogonadism and Infertility. J Neurosci 36:3506-18
Baumgartner, Joel M; Kwong, Thomas G; Ma, Grace L et al. (2016) A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol 23:1609-17
Meyskens Jr, Frank L; Mukhtar, Hasan; Rock, Cheryl L et al. (2016) Cancer Prevention: Obstacles, Challenges and the Road Ahead. J Natl Cancer Inst 108:
Hussain, Timon; Savariar, Elamprakash N; Diaz-Perez, Julio A et al. (2016) Surgical molecular navigation with ratiometric activatable cell penetrating peptide for intraoperative identification and resection of small salivary gland cancers. Head Neck 38:715-23
Singh, Alok R; Joshi, Shweta; Zulcic, Muamera et al. (2016) PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. PLoS One 11:e0150836
Liu, Lin; Messer, Karen; Baron, John A et al. (2016) A prognostic model for advanced colorectal neoplasia recurrence. Cancer Causes Control 27:1175-85
Nuyen, Brian A; Fox, Rina S; Malcarne, Vanessa L et al. (2016) Excessive Daytime Sleepiness as an Indicator of Depression in Hispanic Americans. Hisp Health Care Int 14:116-23
Ghosh, Pradipta; Aznar, Nicolas; Swanson, Lee et al. (2016) Biochemical, Biophysical and Cellular Techniques to Study the Guanine Nucleotide Exchange Factor, GIV/Girdin. Curr Protoc Chem Biol 8:265-298
Johns, Claire; Seav, Susan M; Dominick, Sally A et al. (2016) Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. Breast Cancer Res Treat 156:415-26

Showing the most recent 10 out of 699 publications